Skip to main content
. 2021 Apr 22;10(9):1830. doi: 10.3390/jcm10091830

Table 4.

Relationship between MRS on platform therapy before switching to the second-line treatment and NEDA-3 in the first year of treatment with natalizumab or fingolimod.

MRS = 0 MRS = 1 MRS = 2 MRS = 3 Chi2 Pearson
R Spearman
All NEDA-3
No-NEDA-3
5 (71.4%)
2 (28.6%)
10 (62.5%)
6 (37.5%)
118 (65.9%)
61 (34.1%)
14 (41.2%)
20 (58.8%)
p = 0.05248
p = 0.02743

IFNs, interferons; MRS, modified Rio score; NEDA, no evidence of disease activity.